Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–161 of 161 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: interferon alfa-2a Clear all

Conditions: Hepatitis C, Chronic
Interventions: Sofosbuvir, RBV, PEG; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 44
States / cities: Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more

Conditions: Hepatitis C
Interventions: Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo; Biological · Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon alfa-2a, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 9
States / cities: Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression, HIV Infections
Interventions: Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteosarcoma
Interventions: Etoposide, Interferon Alpha; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 5 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: recombinant interferon alfa, oblimersen sodium, pharmacological study; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hepatitis C
Interventions: Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV); Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more

Conditions: Hepatitis C, Hepatitis C, Chronic
Interventions: thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 54
States / cities: Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more

Conditions: Colorectal Neoplasms
Interventions: 5-fluorouracil; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis C Infection, Genotype 1
Interventions: recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: HanAll BioPharma Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 6
States / cities: Los Angeles, California • National City, California • Miami, Florida + 3 more

Conditions: HIV Infection, Hepatitis C Infection
Interventions: Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more

Conditions: Hepatitis C, Medication Adherence
Interventions: enhanced DOT (both pegylated interferon alfa-2a and ribavirin), standard DOT (PEG-DOT control arm); Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hepatitis C, Hepatitis
Interventions: Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 67
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more

Conditions: Chronic Hepatitis C
Interventions: Pegylated Interferon/ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 5 Years to 18 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Leukemia
Interventions: Recombinant Interferon Alfa, Cytarabine, Omacetaxine Mepesuccinate; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin, telaprevir; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer

A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Directly Observed Hepatitis C Treatment in Methadone Clinics

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C